Mr. Guo: BioPharm Asia debuted as a publicly traded company on the U.S. stock market in May 2009 through a reverse merger with Domain Registration Corp., a Nevada corporation. The company changed its ticker symbol from DOMR to BFAR on Aug. 28, 2009. Currently, there are 50 million BFAR shares outstanding. BioPharm Asia is well diversified with operations in growing, manufacturing, wholesale distribution and retailing of pharmaceutical products, both Western and traditional Chinese. Its robust revenue growth - 22% year-over-year in the quarter ended June 30, 2009 - has been driven mainly by rising sales in our wholesale operations, though sales from new retail stores are starting to have an impact. Our operations are based primarily in Northeast China and are organized into the two divisions, "Pharmacy" and "Herb." In 2008 our revenue was roughly 20 million.
TWST: Would you describe some of the products in your pipeline?
Mr. Guo: We produce both Western medicine and traditional Chinese Eastern medicines. Our focus, however, is the development and distribution of our traditional Chinese medicine line. Our company is engaged in planting and processing our own herbs, which allows us to better ensure the highest quality of our traditional medicines. On our pharmaceutical side, we are heavily focused on logistics and distribution. On our wholesale side, we are a leading distributor of household medicines, chemical agents, antibiotics, biochemistry drugs and biological preparations to hospitals and drugstores throughout China.
Tickers included in this excerpt: BFAR.OB
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.